Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: CHRISTOPHER  PACK
Organization: METACLIPSE THERAPEUTICS CORPORATION
Fiscal Year: 2020
Award: $2,199,976
Funding agency: National Institute of Allergy and Infectious Diseases

Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly).  There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly.  
Animal testing will begin  using VLP with antigen and cytokines, this process will be optimized for GMP and scale-up.

Terms: <2019 novel coronavirus><2019-nCoV><Animal Testing><Antigens><Data><Development><Edodekin Alfa><Elderly><Engineering><GM-CSF><Granulocyte-Macrophage Colony-Stimulating Factor><Histamine-Producing Cell-Stimulating Factor><IL-12><IL12><Immune response><Immunological response><Interleukin-12><Membrane><Molgramostin><NKSF><Natural Killer Cell Stimulatory Factor><Process><Proteins><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><TC-GM-CSF><Tumor-Cell Human GM Colony-Stimulating Factor><Vaccine Design><Vaccines><Virus-like particle><Wuhan coronavirus><advanced age><cytokine><developmental><elders><geriatric><granulocyte macrophage colony stimulating factor><host response><immunogen><immunoresponse><late life><later life><membrane structure><older adult><older person><scale up><senior citizen><virus-like nanoparticles><viruslike particle>